You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

426 Results
Guidelines and Advice
Status: Current
ID: ES 6-25
Oct 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
vinCRIStine,
dexamethasone,
mercaptopurine,
calaspargase pegol,
methotrexate,
cytarabine,
hydrocortisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Drug
Other Name(s): Jemperli
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Document
Dec 2024
Document
Dec 2024
Document
Dec 2024
Document
Dec 2024
Document
Dec 2024
Document
Dec 2024
Document
Dec 2024
Document
Dec 2024
Document
Jan 2025

Pages